NEW YORK, Jan. 12, 2018 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Aradigm Corporation (“Aradigm” or the “Company”) (NASDAQ:ARDM) in the United States District Court for the Northern District of California on behalf of a class consisting of investors who purchased or otherwise acquired Aradigm securities on the open market from July 27, 2017 through January 8, 2018, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the methodology underlying the Company’s Linhaliq Phase III clinical trials was not well tailored to yield consistent efficacy findings or to provide data sufficient to account for discordant efficacy findings; (2) the endpoint of the Phase III trials — namely, delaying the time to first exacerbation on study therapy compared to placebo over approximately one year of observation — was unlikely to demonstrate a clinically meaningful benefit with respect to a patient population that would likely be taking the drug for a longer duration; (3) accordingly, these studies were unlikely to support FDA approval of the Linhaliq NDA; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm prior to the March 12, 2018 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



